Q4 25 EPS
$-0.29
BEAT +11.83%
Est. $-0.33
Q4 25 Revenue
$0
MISS 100.00%
Est. $500,400
vs S&P Since Q4 25
+95.0%
BEATING MARKET
TNGX +107.3% vs S&P +12.3%
Full Year 2025 Results
FY 25 EPS
$-0.87
BEAT +3.10%
Est. $-0.90
FY 25 Revenue
$62.4M
MISS 0.81%
Est. $62.9M
Market Reaction
Did TNGX Beat Earnings? Q4 2025 Results
Tango Therapeutics entered a distinctly transitional phase in Q4 2025, reporting zero revenue against a consensus estimate of $508,000, a -100% miss that was fully anticipated given the company had already recognized all remaining deferred revenue fr… Read more Tango Therapeutics entered a distinctly transitional phase in Q4 2025, reporting zero revenue against a consensus estimate of $508,000, a -100% miss that was fully anticipated given the company had already recognized all remaining deferred revenue from its Gilead collaboration in Q3. The quarter's net loss widened to $38.75 million, or $0.29 per share, compared to a $30.76 million loss in Q4 2024, while R&D spending held roughly flat at $32.10 million as investment shifted toward lead asset vopimetostat and away from discontinued programs. The real story, however, is what comes next: with $343 million in cash providing runway into 2028, Tango is positioning vopimetostat as the preferred PRMT5 inhibitor partner for RAS-targeted therapies, including a newly announced collaboration with Erasca that sent shares surging to a fresh 52-week high. A pivotal monotherapy study in second-line MTAP-deleted pancreatic cancer is slated to begin in 2026, alongside expected combination data readouts with Revolution Medicines' RAS(ON) inhibitors, giving investors several meaningful clinical inflection points on the horizon.
Key Takeaways
- • Accelerated recognition of all remaining Gilead deferred revenue in Q3 2025 following truncation of collaboration agreement
- • Decreased spend on discontinued clinical programs TNG908 and TNG348 reduced full-year R&D expenses
- • Increased investment in vopimetostat, TNG456, and TNG961 clinical advancement
TNGX YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
TNGX Revenue by Segment
With YoY comparisons, source: SEC Filings
“We enter 2026 with a clear focus on execution, building on the significant progress achieved across our development portfolio in 2025. Our lead clinical program, vopimetostat, continues to demonstrate best-in-class potential, and we are on track to launch our first pivotal study in 2L pancreatic cancer this year. Strong enrollment continues in the combination study with Revolution Medicines' RAS(ON) inhibitors, and we are encouraged by the early safety and efficacy data. Given the differentiated profile of vopimetostat enabling the potential for efficacious and tolerable RAS inhibitor combinations, we have entered into a supply agreement with Erasca for its pan-RAS molecular glue ERAS-0015 to further explore the potential of vopimetostat as the preferred PRMT5 inhibitor for combination therapy in pancreatic cancer and other tumor types. These activities are supported by our robust balance sheet, which provides cash runway into 2028, and plans to allocate capital with discipline in areas where we are best positioned to create significant value for patients.”
— Malte Peters, Q4 2025 Earnings Press Release
TNGX Earnings Trends
TNGX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TNGX EPS Trend
Earnings per share: estimate vs actual
TNGX Revenue Trend
Quarterly revenue: estimate vs actual
TNGX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.31 | $-0.32 | -1.72% | $0 | -100.00% |
| Q4 25 BEAT FY | $-0.33 | $-0.29 | +11.83% | $0 | -100.00% |
| FY Full Year | $-0.90 | $-0.87 | +3.10% | $62.4M | -0.81% |
| Q3 25 BEAT | $-0.07 | $0.13 | +287.32% | $53.8M | +30.47% |
| Q2 25 MISS | $-0.34 | $-0.35 | -1.92% | $3.2M | -52.55% |
| Q1 25 MISS | $-0.35 | $-0.36 | -4.08% | $5.4M | -19.84% |